Relay Therapeutics, Inc. (RLAY) — Stock Score Summary

Relay Therapeutics, Inc. (RLAY) has a MoatMap StockRank of 45/100 based on Quality (31/100), Value (34/100), and Momentum (67/100) factor scores. The current signal is HOLD. A clinical-stage biotechnology company focused on drug discovery. Despite interesting computational chemistry platforms, it lacks structural cash flows, high ROIC, or immediate thematic alignment with our 18-month macro views.

Relay Therapeutics, Inc. is a clinical-stage precision medicine company focused on transforming drug discovery through its proprietary Dynamo platform. The company's competitive moat lies in its ability to integrate computational and experimental technologies to analyze protein motion, enabling the targeting of previously undruggable disease drivers. It operates as a leading-edge biotechnology innovator specializing in precision oncology and genetic diseases.

Key Financial Metrics

Price$14.09
Market Cap$3.0B
P/E (Forward)-8.70
Price/Book4.46
Return on Equity-40.0%
Return on Invested Capital-50.8%
Debt/Equity4.92
Gross Margin0.0%
Operating Margin-2619.7%
Revenue Growth-60.9%
Free Cash Flow$-121M

Relay Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Relay Therapeutics, Inc.’s (RLAY) StockRank?
MoatMap’s StockRank for Relay Therapeutics, Inc. (RLAY) is 45/100, with a Hold signal. It is a composite of Quality (31), Value (34), and Momentum (67) factor ranks across MoatMap’s 19,000+ stock universe.
Does Relay Therapeutics, Inc. have an economic moat?
Relay Therapeutics, Inc. (RLAY) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Relay Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Relay Therapeutics, Inc. (RLAY) is Hold, based on a StockRank of 45/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Relay Therapeutics, Inc. in?
Relay Therapeutics, Inc. (RLAY) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksRLAY deep dive reportAI ChampionsHow we score stocksSense-check another stock